Name: Chemogenetic Regulation in Reprogrammed Stem Cell-derived Precursor Cells in Treating Neurodegenerative Diseases (Video) | JoVE Journal
Uploaded: 2025-05-02T14:00:00.000+00:00
Duration: 9 min 44 s
Description: Learn chemogenetic regulation of reprogrammed stem cell-derived dopaminergic precursors for treating Parkinson's disease in mouse models. This protocol enables precise neuronal control and functional recovery assessment.

ai_agent_IP

ai_agent

maintenance

instantTrialDurationMinutes

isBiopharma

enableNewMyJoveSectionDesign

educationFeatures

seoMetaApi

ai_copilot_institution_blacklist

ai_chat_institution_blacklist

freeAccessWindow

ssoRoleCapture

scheduledMaintenanceBanner

joveLabsFeatures

disable_autoplay_for_bots

extended_trial_duration

5 minutes

This work was supported by the Beijing Natural Science Foundation (7242068), National Natural Science Foundation of China (82171250), Beijing Municipal Health Commission Fund (PXM2020_026283_000005) and The Project for Technology Development of Beijing-affiliated Medical Research Institutes (11000023T000002036310).

All animal experiments were performed in accordance with the guidelines set forth by the Beijing Association for Laboratory Animal Science and the National Institutes of Health for the Care and Use of Laboratory Animals. Human peripheral blood mononuclear cells (PBMCs) were obtained from a healthy donor with written informed consent as described in a previous study17.
1. Construction of non-fusion DREADD stem-based cell lines
<ol>
	<li>Construct the DREADD donor plasmid. 
	NOTE: The digestion sites should be designed according to the vector sequence. Fragments should be synthesized and amplified with 20-30 bp overlaps matching the fragment arms to enhance assembly efficiency.
	<ol>
		<li>Design and synthesize the T2A-ZsGreen fragment (Fragment I).</li>
		<li>Amplify the hM3Dq/hM4Di-T2A fragment from the original plasmid using PCR (Fragment II). Set up the PCR reaction (50 &#181;L total volume) to contain 1x PCR buffer, 200 &#181;M of each dNTP mix, 0.5 &#181;M forward and reverse primers, 10-50 ng of plasmid DNA template, and 1.25 U of high-fidelity DNA polymerase. Perform thermocycling under the following conditions: initial denaturation at 98 &#176;C for 2.75 min to fully denature the template; 32 amplification cycles consisting of 98 &#176;C for 15 s (denaturation), 60 &#176;C for 30 s (primer annealing), and 72 &#176;C for 60 s (extension); final extension at 72 &#176;C for 7 min.</li>
		<li>Digest the vector plasmid with the appropriate enzyme to obtain the linearized vector. Purify all fragments by agarose gel electrophoresis and quantify them using a spectrophotometer. 
		NOTE: Here, the original plasmid was digested with MluI and SalI.</li>
	</ol>
	</li>
	<li>Gently mix 50-100 ng of the linearized vector, Fragment I, and Fragment II in a 1:3:3 molar ratio, along with 2x Cloning Mix. Incubate the mixture at 55 &#176;C for 1 h to facilitate homologous recombination through Gibson Assembly.</li>
	<li>Insert the guide RNA targeting the AAVS1 site into the BbsI site of the pX458 vector. 
	NOTE: Perform sequence verification on all constructed plasmids using Sanger sequencing.</li>
	<li>Maintain the reprogrammed stem cells in the media, aiming for a cell density of 2-5 &#215; 106 cells/mL. 
	NOTE: The reprogrammed stem cells used here were induced from human PBMCs as described in a previous study17. Monitoring cell health is essential, as cell status significantly impacts electroporation efficiency. See Table of Materials for a comparison of the media.</li>
	<li>Mix 2-5 &#215; 106 cells, 2 &#181;g of each donor plasmid (hM4Di-T2A-ZsGreen or hM3Dq-T2A-ZsGreen), and 2 &#181;g of gRNA plasmid in 100 &#181;L of electroporation buffer and transfer into a cuvette for electroporation. 
	NOTE: Ensure that the mixture is well-mixed and free of bubbles before proceeding to electroporation. Optimize electroporation parameters based on cell type to maximize transfection efficiency, as different devices may require specific adjustments.</li>
	<li>Set the Nucleofector to the B16 program and initiate electroporation to facilitate efficient transfection of the target iNSCs.</li>
	<li>Add 1 mL of 50 &#181;g/mL poly-D-lysine (PDL) to each well of a 6-well plate and incubate at room temperature for at least 2 h. Remove all PDL from the wells and add 1.5 mL of a 5 &#181;g/mL laminin to each well and incubate at 37 &#176;C for 2-4 h. Use the coated plate immediately or store at 2-8 &#176;C for 1 week.</li>
	<li>Transfer the electroporated cells into six-well plates that have been coated with PDL and laminin. Distribute approximately 500,000 cells per well in a volume of 2 mL of culture medium per well.</li>
	<li>After 72 h of electroporation, use a flow cytometer to sort fluorescent positive cells.
	<ol>
		<li>Resuspend dissociated cells in DPBS, and filter through a 70 &#181;m cell strainer.</li>
		<li>Configure the sorter with FITC channel for ZsGreen detection. Include untreated iNSCs as negative controls to define the baseline fluorescence.</li>
		<li>Calibrate the instrument using 100 &#181;m nozzles at 20 psi sheath pressure. Implement a four-way purity sort mode with single-cell confirmation.</li>
	</ol>
	</li>
	<li>Plate single ZsGreen+ cells in 96-well plates precoated with PDL and laminin, and add 200 &#181;L of culture medium per well to support initial growth. Maintain in culture medium for 7-14 days 
	NOTE: Monitor wells daily for signs of growth and fluorescence indicating successful integration and label the positive well.</li>
	<li>Isolate single clones exhibiting fluorescence using an inverted fluorescence microscope equipped with a GFP filter set. Screen clones at 10x magnification. Mark wells containing monoclonal colonies with sustained, uniform ZsGreen signal. Capture brightfield and fluorescence images to document morphology and fluorescence intensity. 
	NOTE: Prior to imaging, replace fresh medium to reduce background fluorescence. Exclude colonies with irregular morphology or autofluorescence.</li>
	<li>Expand the positive cells on coated 48-well plates. Then split into two parts, one for culture and the other for genotyping.</li>
	<li>Extract genomic DNA from candidate clones.Prepare PCR reactions with two primer pairs: one pair to confirm insertion of the gene of interest, the other primer to distinguish homozygous and heterozygous clones. Perform thermocycling under the following conditions: initial denaturation at 95 &#176;C for 5 min; 38 cycles of 95 &#176;C for 30 s, 60 &#176;C for 30 s, and 72 &#176;C for 45 s; final extension at 72 &#176;C for 7 min. Resolve PCR products on a 2% agarose gel. 
	NOTE: See Table of Materials for the primers. Confirm insertion of the gene of interest by a single 650 bp band (primer 1). Identify heterozygous clones by the presence of a single 630 bp band and homozygous clones by the absence of this band (primer 2).</li>
	<li>Expand the positive cells on coated six-well plates.</li>
	<li>Digest the cells and wash them in phosphate-buffered saline (PBS) by centrifugation at 250 &#215; g for 3 min. Freeze the cells in cryopreservation medium with 10% DMSO at a density of 2.5 &#215; 106 cells per vial.</li>
</ol>
2. Transplanted DREADD stem cell-derived precursor cells into PD model mice
<ol>
	<li>Administer an intraperitoneal injection of desipramine at a concentration of 5 mg/mL (10 mg/kg) to immunodeficient mice 30 min prior to surgery. Anesthetize the mice with 2% isoflurane.</li>
	<li>Conduct unilateral stereotaxic injections of 3 &#181;L of 6-hydroxydopamine (6-OHDA, 5 &#181;g/&#181;L). Target the right corpus striatum using the following coordinates: anteroposterior = 0.5 mm, lateral = 2.1 mm, and vertical = -3.2 mm. 
	NOTE: 6-OHDA should be dissolved in saline containing 0.2% ascorbic acid. Ensure precise targeting to minimize variability in lesion severity. 
	CAUTION: 6-OHDA is cytotoxic and produces reactive oxygen species that induce cellular stress. Handle with care.</li>
	<li>Administer an intraperitoneal injection of apomorphine (1 mg/kg, 0.5 mg/mL dissolved in saline) to validate the lesions 4 weeks post surgery.Select lesioned mice that exhibit more than 100 contralateral rotations within a 30 min observation period for subsequent experiments. 
	NOTE: Apomorphine is a dopamine receptor agonist, which directly activates supersensitive postsynaptic receptors in the denervated striatum, unbalancing bilateral nigrostriatal circuit activity. Apomorphine-induced rotation serves to evaluate the severity of unilateral dopaminergic lesions by 6-OHDA.</li>
	<li>Seed and culture cells in coated six-well plates (150,000 cells per well). Incubate in Phase 1 differentiation medium for 10 days, refreshing the medium every 2 days. On Day 11, switch to Phase 2 differentiation medium and continue incubation until Day 13, changing the medium each day. 
	NOTE: See Table of Materials for a comparison of differentiation medium.</li>
	<li>Harvest the cells on Days 10 and 13 of differentiation, then mix them at a ratio of 1:7. Suspend the mixture in transplantation buffer at a concentration of 100,000 cells/&#181;L. 
	NOTE: See Table of Materials for a comparison of transplantation buffer.</li>
	<li>Administer a stereotaxic injection of a total volume of 4 &#181;L of the prepared cell suspension into a PD mouse.</li>
	<li>Perform the cylinder test at various time points post cell transplantation. Place a glass beaker (diameter: 20 cm, height: 30 cm) on a flat, non-reflective surface. Position a top-view camera above the cylinder to capture the full diameter. 
	NOTE: Enclose the cylinder with black curtains to eliminate external visual stimuli.</li>
	<li>Place each mouse in the center of the cylinder and initiate simultaneous video recording (3 min/session). After the session, return the mouse to its home cage. 
	NOTE: Acclimate mice to the testing room for 30 min under light conditions. Clean the cylinder with 70% ethanol between trials to eliminate olfactory cues.</li>
	<li>Assess the upper limb movement capability of the mice for 3 min. Calculate the number of wall contacts made by the impaired forelimb relative to the total number of contacts made by both forelimbs.</li>
	<li>Administer either saline or CNO at a dosage of 1.2 mg/kg via intraperitoneal injection. Conduct the cylinder test to assess behavioral modulation in the PD mouse model following CNO administration 
	NOTE: Allow a recovery period of approximately 40 min before proceeding with the assessment.</li>
</ol>
3.&#160;In vivo electrophysiological profiling of chemogenetically modulated cells
<ol>
	<li>Anesthetize mice by an intraperitoneal injection of 250 mg/kg pentobarbital. Extract the brain and immediately place it in ice-cold sucrose-based artificial cerebrospinal fluid (s-ACSF) to maintain cellular integrity. Using a vibratome, slice the brain into sections of 300-400 &#181;m thickness. 
	NOTE: Work quickly to keep the brain at low temperatures to preserve cellular function. See Table of Materials for the s-ACSF used in fresh brain section preparation.</li>
	<li>Transfer the samples to a chamber filled with ACSF equilibrated with 95% O2 and 5% CO2 at 34 &#176;C, ensuring that this temperature is maintained throughout the experiment. 
	NOTE: See Table of Materials for ACSF.</li>
	<li>Load glass pipettes with iced intracellular solution, with electrode resistance ranging from 7 to 10 M&#937;. 
	NOTE: See Table of Materials for intracellular solution. Glass pipettes are made from glass capillaries by a micropipette puller18. Check for any leaks in the glass pipettes before starting experiments, ensuring that the tips are sharp enough to penetrate the cell membrane. Prepare pipettes quickly to minimize temperature fluctuations in the intracellular solution.</li>
	<li>Mount slices in a submerged recording chamber superfused (2 mL/min) with oxygenated ACSF at 34 &#176;C. Position pipettes using motorized micromanipulators under infrared differential interference contrast microscopy. Establish whole-cell configuration by applying gentle suction (resistance &#62; 1 G&#937;) to patched neurons within graft regions. Clamp cells at -70 mV using a patch-clamp amplifier; acquire baseline sEPSCs for 8 min at 10 kHz sampling rate (filtered at 2 kHz), and continuously monitor access resistance (target: &#60;20 M&#937;; discard if &#62;25 M&#937; or fluctuating &#62;10%). 
	NOTE: Use appropriate pressure when applying suction to avoid undesirable cell displacement or rupture, and carefully adjust the pipette position to achieve a good seal. If the seal quality is poor, discard the pipette and try again.</li>
	<li>Add 50 &#181;M CNO to the recording chamber immediately after completing the baseline measurement and continue recording data for an additional 16 min while observing changes in sEPSC frequency or amplitude.</li>
	<li>Perform a washout procedure by replacing the CNO solution with fresh ACSF to effectively remove CNO from the recording chamber. Continue recording data for the remainder of the experiment to evaluate any recovery in synaptic activity.</li>
</ol>

<ol><li>Thiel, G. <a target="_blank" href="http://scholar.google.com/scholar?hl=en&safe=off&q=author%3aThiel%2C+G+%22Designer+receptors+exclusively+activated+by+designer+drugs%22">Designer receptors exclusively activated by designer drugs</a>. , Humana Press. (2015).</li>
<li>Roth, B. L. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Dreadds+for+neuroscientists%5BTitle%5D)+AND+%22Neuron%22%5BJournal%5D)">Dreadds for neuroscientists.</a> Neuron. 89 (4), 683-694 (2016).</li>
<li>Gomez, J. L., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Chemogenetics+revealed%3A+DREADD+occupancy+and+activation+via+converted+clozapine%5BTitle%5D)+AND+%22Science%22%5BJournal%5D)">Chemogenetics revealed: DREADD occupancy and activation via converted clozapine.</a> Science. 357 (6350), 503-507 (2017).</li>
<li>Chehelgerdi, M., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Exploring+the+promising+potential+of+induced+pluripotent+stem+cells+in+cancer+research+and+therapy%5BTitle%5D)+AND+%22Mol+Cancer%22%5BJournal%5D)">Exploring the promising potential of induced pluripotent stem cells in cancer research and therapy.</a> Mol Cancer. 22 (1), 189(2023).</li>
<li>Song, J., Patel, R. V., Sharif, M., Ashokan, A., Michaelides, M. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Chemogenetics+as+a+neuromodulatory+approach+to+treating+neuropsychiatric+diseases+and+disorders%5BTitle%5D)+AND+%22Mol+Ther%22%5BJournal%5D)">Chemogenetics as a neuromodulatory approach to treating neuropsychiatric diseases and disorders.</a> Mol Ther. 30 (3), 990-1005 (2022).</li>
<li>Parmar, M., Grealish, S., Henchcliffe, C. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((The+future+of+stem+cell+therapies+for+Parkinson+disease%5BTitle%5D)+AND+%22Nat+Rev+Neurosci%22%5BJournal%5D)">The future of stem cell therapies for Parkinson disease.</a> Nat Rev Neurosci. 21 (2), 103-115 (2020).</li>
<li>Dell'anno, M. T., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Remote+control+of+induced+dopaminergic+neurons+in+Parkinsonian+rats%5BTitle%5D)+AND+%22J+Clin+Invest%22%5BJournal%5D)">Remote control of induced dopaminergic neurons in Parkinsonian rats.</a> J Clin Invest. 124 (7), 3215-3229 (2014).</li>
<li>Chen, Y., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Chemical+control+of+grafted+human+PSC-derived+neurons+in+a+mouse+model+of+Parkinson%27s+disease%5BTitle%5D)+AND+%22Cell+Stem+Cell%22%5BJournal%5D)">Chemical control of grafted human PSC-derived neurons in a mouse model of Parkinson's disease.</a> Cell Stem Cell. 18 (6), 817-826 (2016).</li>
<li>Bjorklund, A., Parmar, M. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Dopamine+cell+therapy%3A+From+cell+replacement+to+circuitry+repair%5BTitle%5D)+AND+%22J+Parkinsons+Dis%22%5BJournal%5D)">Dopamine cell therapy: From cell replacement to circuitry repair.</a> J Parkinsons Dis. 11 (S2), S159-S165 (2021).</li>
<li>Alcacer, C., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Chemogenetic+stimulation+of+striatal+projection+neurons+modulates+responses+to+Parkinson%27s+disease+therapy%5BTitle%5D)+AND+%22J+Clin+Invest%22%5BJournal%5D)">Chemogenetic stimulation of striatal projection neurons modulates responses to Parkinson's disease therapy.</a> J Clin Invest. 127 (2), 720-734 (2017).</li>
<li>Alexander, G. M., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Remote+control+of+neuronal+activity+in+transgenic+mice+expressing+evolved+G+protein-coupled+receptors%5BTitle%5D)+AND+%22Neuron%22%5BJournal%5D)">Remote control of neuronal activity in transgenic mice expressing evolved G protein-coupled receptors.</a> Neuron. 63 (1), 27-39 (2009).</li>
<li>Stachniak, T. J., Ghosh, A., Sternson, S. M. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Chemogenetic+synaptic+silencing+of+neural+circuits+localizes+a+hypothalamus+midbrain+pathway+for+feeding+behavior%5BTitle%5D)+AND+%22Neuron%22%5BJournal%5D)">Chemogenetic synaptic silencing of neural circuits localizes a hypothalamus midbrain pathway for feeding behavior.</a> Neuron. 82 (4), 797-808 (2014).</li>
<li>Kang, H. J., Minamimoto, T., Wess, J., Roth, B. L. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Chemogenetics+for+cell-type-specific+modulation+of+signalling+and+neuronal+activity%5BTitle%5D)+AND+%22Nat+Rev+Methods+Primers%22%5BJournal%5D)">Chemogenetics for cell-type-specific modulation of signalling and neuronal activity.</a> Nat Rev Methods Primers. 3 (1), 93(2023).</li>
<li>Miyanishi, K., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Behavioral+tests+predicting+striatal+dopamine+level+in+a+rat+hemi-Parkinson%27s+disease+model%5BTitle%5D)+AND+%22Neurochem+Int%22%5BJournal%5D)">Behavioral tests predicting striatal dopamine level in a rat hemi-Parkinson's disease model.</a> Neurochem Int. 122, 38-46 (2019).</li>
<li>Zheng, X., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Human+IPSC-derived+midbrain+organoids+functionally+integrate+into+striatum+circuits+and+restore+motor+function+in+a+mouse+model+of+Parkinson%27s+disease%5BTitle%5D)+AND+%22Theranostics%22%5BJournal%5D)">Human IPSC-derived midbrain organoids functionally integrate into striatum circuits and restore motor function in a mouse model of Parkinson's disease.</a> Theranostics. 13 (8), 2673-2692 (2023).</li>
<li>Xiong, M., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Human+stem+cell-derived+neurons+repair+circuits+and+restore+neural+function%5BTitle%5D)+AND+%22Cell+Stem+Cell%22%5BJournal%5D)">Human stem cell-derived neurons repair circuits and restore neural function.</a> Cell Stem Cell. 28 (1), 112-126.e6 (2021).</li>
<li>Yuan, Y., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Dopaminergic+precursors+differentiated+from+human+blood-derived+induced+neural+stem+cells+improve+symptoms+of+a+mouse+Parkinson%27s+disease+model%5BTitle%5D)+AND+%22Theranostics%22%5BJournal%5D)">Dopaminergic precursors differentiated from human blood-derived induced neural stem cells improve symptoms of a mouse Parkinson's disease model.</a> Theranostics. 8 (17), 4679(2018).</li>
<li>Zhu, M., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Preparation+of+acute+spinal+cord+slices+for+whole-cell+patch-clamp+recording+in+substantia+gelatinosa+neurons%5BTitle%5D)+AND+%22J+Vis+Exp%22%5BJournal%5D)">Preparation of acute spinal cord slices for whole-cell patch-clamp recording in substantia gelatinosa neurons.</a> J Vis Exp. (143), (2019).</li>
<li>Wang, X., Han, D., Zheng, T., Ma, J., Chen, Z. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Modulation+of+human+induced+neural+stem+cell-derived+dopaminergic+neurons+by+DREADD+reveals+therapeutic+effects+on+a+mouse+model+of+Parkinson%27s+disease%5BTitle%5D)+AND+%22Stem+Cell+Res+Ther%22%5BJournal%5D)">Modulation of human induced neural stem cell-derived dopaminergic neurons by DREADD reveals therapeutic effects on a mouse model of Parkinson's disease.</a> Stem Cell Res Ther. 15 (1), 297(2024).</li>
<li>Iancu, R., Mohapel, P., Brundin, P., Paul, G. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Behavioral+characterization+of+a+unilateral+6-OHDA-lesion+model+of+Parkinson%27s+disease+in+mice%5BTitle%5D)+AND+%22Behav+Brain+Res%22%5BJournal%5D)">Behavioral characterization of a unilateral 6-OHDA-lesion model of Parkinson's disease in mice.</a> Behav Brain Res. 162 (1), 1-10 (2005).</li>
<li>Surmeier, D. J., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((The+role+of+dopamine+in+modulating+the+structure+and+function+of+striatal+circuits%5BTitle%5D)+AND+%22Prog+Brain+Res%22%5BJournal%5D)">The role of dopamine in modulating the structure and function of striatal circuits.</a> Prog Brain Res. 183, 148-167 (2010).</li>
</ol>

The authors have no conflicts of interest to disclose.

This protocol utilized CRISPR technology to engineer human reprogrammed stem cells to express excitatory hM3Dq and inhibitory hM4Di receptors. The modulation of neuronal activity by CNO was assessed through cell transplantation into mouse models of Parkinson's disease, accompanied by behavioral assessments and electrophysiological recordings.
The first critical step in generating stably expressed, non-fusion DREADD constructs in chemogenetically reprogrammed stem cells involves the T2A-ZsGreen...

Designer receptors exclusively activated by designer drugs (DREADD) are engineered G-protein coupled receptors that can be selectively activated by otherwise inert synthetic ligands1. The chemogenetic approach has become an essential tool in neuroscience by enabling researchers to investigate neural circuit connectivity with high precision and enhancing our understanding of cellular functions both in vivo and in vitro through the selective activation or inhibition of specific brain regions or cell types2,3.
Stem cell-based therapy presents a promising strategy for treating neurodegenerative diseases. The efficacy of graft cells relies on proper integration, survival, and functional contribution to host tissues. Uncontrolled cellular activity can lead to negative consequences, including tumorigenesis4; necessitating precise control of these cells post transplantation. Leveraging DREADD technology in human reprogrammed stem cells and derived neurons provides a means to precisely control neuronal activity via the administration of the designer drug CNO2,5. In the context of Parkinson&#39;s disease (PD), which is characterized by the loss of dopaminergic neurons, manipulating the activity of stem cell-derived dopaminergic neurons is crucial for investigating their synaptic inputs and projection patterns in rodent models6,7,8,9,10. Incorporating excitatory hM3Dq and inhibitory hM4Di receptors into these models enables precise modulation of neuronal activity11,12.
The combination of animal behavioral assessments and electrophysiological recordings allows for a comprehensive evaluation of the effects of chemogenetic modulation on transplanted cells in vivo13. Behavioral assessments, including apomorphine-induced rotation, the cylinder test, and the rotarod test, evaluate motor coordination and provide insights into changes in motor function associated with experimental models of PD14. Electrophysiological techniques, such as patch-clamp recordings, enable real-time monitoring of synaptic responses and action potentials, providing a comprehensive view of how transplanted cells integrate into existing neural networks15. By combining behavioral assessments with electrophysiological evaluations, we can investigate how chemogenetic modulation affects the integration and functionality of these cells within host neural circuits16. Preliminary findings suggest that CNO administration effectively modulates neuronal activity in transplanted cells, resulting in improved functional outcomes in animal models.
In this protocol, human reprogrammed stem cells were engineered to express hM3Dq or hM4Di receptors by using clustered regularly interspaced short palindromic repeats (CRISPR) technology. After differentiating modified reprogrammed stem cells into midbrain dopaminergic precursor cells, these cells were transplanted into mouse models of PD to assess their integration and functional regulation within the host neural circuits using behavioral assessments and electrophysiological recordings.

<table><tbody><tr><td>2 x Rapid Taq Master Mix</td><td>Vazyme</td><td>P222-01</td><td>used for genotyping analysis</td></tr><tr><td>2&amp;times;Seamless Cloning Mix</td><td>Biomed Gene Tech.</td><td>CL117-01</td><td>used for plasmid construction</td></tr><tr><td>6-OHDA</td><td>Sigma-Aldrich</td><td>H4381</td><td>used for establishing PD mice model</td></tr><tr><td>AAVS1-Pur-CAG-EGFP</td><td>Addgene</td><td>80945</td><td>used as control&amp;nbsp;</td></tr><tr><td>AAVS1-Pur-CAG-hM4Di-mCherry</td><td>Addgene</td><td>80947</td><td>original plasmid for construction of hM4Di-T2A-ZsGreen</td></tr><tr><td>AAVS1-Pur-CAG-hM3Dq-mCherry</td><td>Addgene</td><td>80948</td><td>original plasmid for construction of hM3Dq-T2A-ZsGreen</td></tr><tr><td>AAVS1-CAG-hM4Di-T2A-ZsGreen</td><td>N/A</td><td>N/A</td><td>Constructed donor plasmid based on #80947</td></tr><tr><td>AAVS1-CAG-hM3Dq-T2A-ZsGreen</td><td>N/A</td><td>N/A</td><td>Constructed donor plasmid based on #80948</td></tr><tr><td>Accutase</td><td>Invitrogen</td><td>A11105-01</td><td>Used for digesting cells</td></tr><tr><td>AMAXA Nucleofector</td><td>Lonza</td><td>AAD-1001S</td><td></td></tr><tr><td>Apomorphine</td><td>Sigma-Aldrich</td><td>A4393</td><td></td></tr><tr><td>Artificial cerebrospinal fluid (ACSF)</td><td>N/A</td><td>N/A</td><td>125 mM NaCl, 2.5 mM KCl, 2 mM CaCl&lt;sub&gt;2&lt;/sub&gt;, 1.25 mM NaH&lt;sub&gt;2&lt;/sub&gt;PO&lt;sub&gt;4&lt;/sub&gt;, 1 mM MgSO&lt;sub&gt;4&lt;/sub&gt;, 25 mM glucose, and&amp;nbsp; 26 mM NaHCO&lt;sub&gt;3&lt;/sub&gt;</td></tr><tr><td>Ascorbic acid</td><td>Sigma-Aldrich</td><td>1043003</td><td></td></tr><tr><td>B-27 Supplement</td><td>Gibco</td><td>17504044</td><td></td></tr><tr><td>BDNF</td><td>Peprotech</td><td>450-02</td><td></td></tr><tr><td>cAMP</td><td>Sigma-Aldrich</td><td>D0627</td><td></td></tr><tr><td>CHIR99021</td><td>Yeasen</td><td>53003ES10</td><td></td></tr><tr><td>Clozapine-N-oxide</td><td>Enzo</td><td>BML-NS105</td><td></td></tr><tr><td>DAPT</td><td>Sigma-Aldrich</td><td>D5942</td><td></td></tr><tr><td>Desipramine&amp;nbsp;</td><td>Sigma-Aldrich</td><td>D3900</td><td></td></tr><tr><td>D-glucose</td><td>Sigma-Aldrich</td><td>G5767</td><td></td></tr><tr><td>DMEM/F12</td><td>Gibco</td><td>11330-032</td><td></td></tr><tr><td>DMEM/F12</td><td>Gibco</td><td>11320-033</td><td></td></tr><tr><td>DMSO</td><td>Sigma-Aldrich</td><td>D2650</td><td></td></tr><tr><td>FGF8</td><td>Peprotech</td><td>100-25</td><td></td></tr><tr><td>GDNF</td><td>Peprotech</td><td>450-10</td><td></td></tr><tr><td>GlutaMax</td><td>Gibco</td><td>35050-061</td><td></td></tr><tr><td>Hank&amp;rsquo;s Balanced Salt Solution (HBSS)</td><td>Gibco</td><td>14175095</td><td></td></tr><tr><td>Human leukemia inhibitory factor (hrLIF)</td><td>Millipore</td><td>LIF1010</td><td></td></tr><tr><td>Iced intracellular fluid</td><td>N/A</td><td>N/A</td><td>130 mM K-gluconate, 16 mM KCl, 0.2 mM EGTA, 2 mM MgCl&lt;sub&gt;2&lt;/sub&gt;, 10 mM HEPES, 4 mM Na&lt;sub&gt;2&lt;/sub&gt;-ATP, 0.4 mM Na3-GTP, 0.3% of neurobiotin</td></tr><tr><td>KnockOut Serum Replacement</td><td>Gibco</td><td>10828028</td><td></td></tr><tr><td>Laminin</td><td>Roche</td><td>11243217001</td><td></td></tr><tr><td>Micropipette Puller</td><td>Sutter Instrument Company</td><td>P-1000</td><td></td></tr><tr><td>N-2 Supplement</td><td>Thermo Fisher</td><td>17502048</td><td></td></tr><tr><td>Neurobasal-A Medium</td><td>Gibco</td><td>10888-022</td><td></td></tr><tr><td>Non-essential amino acids (NEAA)</td><td>Gibco</td><td>11140-050</td><td></td></tr><tr><td>PBS</td><td>Gibco</td><td>10010023</td><td></td></tr><tr><td>pCLAMP 11 software suite</td><td>Molecular Devices</td><td>N/A</td><td>Patch-clamp electrophysiology data acquisition and analysis software</td></tr><tr><td>Phase 1 differentiation medium</td><td>N/A</td><td>N/A</td><td>96% DMEM/F12 (Gibco, 11320-033), 1% B-27 Supplement, 1% N-2 Supplement, 1% NEAA, 1% GlutaMax, 1 &amp;micro;M SAG1, and 100 ng/mL FGF8&amp;nbsp;</td></tr><tr><td>Phase 2 differentiation medium&amp;nbsp;</td><td>N/A</td><td>N/A</td><td>96% DMEM/F12 (Gibco, 11320-033), 1% B-27 Supplement, 1% N-2 Supplement, 1% NEAA, and 1% GlutaMax, 10 ng/mL BDNF, 10 ng/mL GDNF, 1 ng/mL TGF-&amp;beta;III, 10 &amp;micro;M DAPT, 0.2 mM ascorbic acid, and 0.5 mM cAMP.</td></tr><tr><td>Poly-D-lysine hydrobromide (PDL)</td><td>Sigma-Aldrich</td><td>P7886</td><td></td></tr><tr><td>Primers for genotyping</td><td>N/A</td><td>N/A</td><td>Insertion Foward: TCTTCACTCGCTGGGTTCCCTT;&lt;br/&gt; Insertion Reverse: CCTGTGGGAGGAAGAGAAGAGGT;&lt;br/&gt; Homozygosity Foward:CGTCTCCCTGGCTTTAGCCA; Homozygosity Reverse: GATCCTCTCTGGCTCCATCG</td></tr><tr><td>pX458</td><td>Addgene</td><td>152199</td><td></td></tr><tr><td>SAG1</td><td>Enzo</td><td>ALX-270-426-M01</td><td></td></tr><tr><td>SB431542</td><td>Yeasen</td><td>53004ES50</td><td></td></tr><tr><td>sucrose-based artificial cerebrospinal fluid (s-ACSF)</td><td></td><td></td><td>234 mM sucrose, 2.5 mM KCl, 26 mM NaHCO3, 1.25 mM NaH2PO4, 11 mM Dglucose, 0.5 mM CaCl2, and 10 mM MgSO4</td></tr><tr><td>Stem cell culture media</td><td>N/A</td><td>N/A</td><td>&amp;nbsp;48% DMEM/F12 (Gibco, 11330-032) and 48% Neurobasal, with the addition of 1% B27, 1% N2, 1% NEAA, 1% GlutaMax, 10 ng/mL hrLIF, 2 &amp;micro;M SB431542, and 3 &amp;micro;M CHIR99021</td></tr><tr><td>TGF-&amp;beta;III</td><td>Peprotech</td><td>100-36E</td><td></td></tr><tr><td>Transplantation buffer</td><td>N/A</td><td>N/A</td><td>HBSS buffer with 5 g/L D-glucose, 100 ng/mL BDNF, 100 ng/mL GDNF, and 0.2 mM ascorbic Acid</td></tr><tr><td>Vibratome</td><td>Leica&amp;nbsp;</td><td>VT1000 S</td><td></td></tr><tr><td>Whole-cell patch-clamp</td><td>Molecular Devices</td><td>&amp;nbsp;MultiClamp700B</td><td></td></tr></tbody></table>

chemogenetic regulation in reprogrammed stem cell-derived precursor cells in treating neurodegenerative diseases

Chemogenetic Regulation in Reprogrammed Stem Cell-derived Precursor Cells in Treating Neurodegenerative Diseases

The integration of designer receptors exclusively activated by designer drugs (DREADD) with stem cell-based therapies presents an advanced strategy for precise neuronal modulation. Here, we utilized CRISPR-engineered human reprogrammed stem cells expressing excitatory (hM3Dq) or inhibitory (hM4Di) DREADD receptors to evaluate the functional integration and modulation of transplanted dopaminergic precursors in a murine model of Parkinson&#39;s disease (PD). Key steps included generating non-fusion DREADD-expressing stem cell lines, differentiating them into midbrain dopaminergic precursors, and transplanting these cells into the striatum of 6-hydroxydopamine (6-OHDA)-lesioned mice. We conducted behavioral assessments and electrophysiological recordings to analyze the effects of the transplanted cells. Behavioral tests, such as the cylinder test, demonstrated significant modulation of motor function following clozapine-N-oxide (CNO) administration. Specifically, activation of hM4Di reduced contralateral forelimb movement, whereas activation of hM3Dq was associated with enhanced motor behavior. Electrophysiological recordings revealed distinct synaptic responses. hM4Di activation increased interevent intervals and decreased peak amplitudes of spontaneous excitatory postsynaptic currents (sEPSCs), whereas hM3Dq activation decreased interevent intervals and increased peak amplitudes, reflecting enhanced excitatory signaling. In summary, the integration of behavioral and electrophysiological assessments validates the precise functional incorporation of engineered chemically reprogrammed stem cells into host neural circuits.

Figure 1 shows the key steps of this methodological approach for engineered human reprogrammed stem cells expressing excitatory (hM3Dq) or inhibitory (hM4Di) DREADD receptors to evaluate the functional integration and modulation of derived dopaminergic precursors in a mouse model of Parkinson's disease (PD). Figure 2 outlines the CRISPR/Cas9-mediated gene knock-in strategy for introducing non-fusion constructs of hM4Di-T2A-ZsGreen and hM3Dq-T2A-ZsGreen into repr...

Here, we describe a protocol for engineering chemically reprogrammed stem cells to achieve precise neuronal modulation by differentiating these cells into dopaminergic precursor cells, transplanting them into mouse models of Parkinson's disease, and evaluating behavioral and electrophysiological outcomes to confirm the successful integration and functional effectiveness of the transplanted cells.

The integration of designer receptors exclusively activated by designer drugs (DREADD) with stem cell-based therapies presents an advanced strategy for ...

chemogenetic-regulation-reprogrammed-stem-cell-derived-precursor

Research

JoVE Journal

Neuroscience

Cortical Neurogenesis: Transitioning from Advances in the Laboratory to Cell-Based Therapies

This video demonstrates the direct reprogramming of genetically modified hematopoietic progenitor cells into neuronal stem cells. Transcription factors expressed by hematopoietic progenitor cells trigger a cascade of molecular events facilitating their transformation. Further specific media is used to select and grow induced neuronal stem cells.

Direct Reprogramming of Hematopoietic Progenitor Cells into Neural Stem Cells

Source: Sharma, A. D., et.al. High Throughput Characterization of Adult Stem Cells Engineered for Delivery of Therapeutic Factors for Neuroprotective Strategies. J. Vis. Exp. (2015)This video demonstrates the process of characterizing transgenic mesenchymal stem cells engineered to express therapeutic neurotrophic factors. It outlines the steps involved in fixing, permeabilizing, and staining the cells with primary and secondary antibodies targeting a cell proliferation marker, followed by...

Characterization of Genetically Engineered Mesenchymal Stem Cells for Neurotherapeutic Applications

This protocol describes a novel mechanical chopping method that allows the expansion of spherical neural stem and progenitor cell aggregates without dissociation to a single cell suspension.  Maintaining cell/cell contact allows rapid and stable growth for over 40 passages.

A cGMP-applicable Expansion Method for Aggregates of Human Neural Stem and Progenitor Cells Derived From Pluripotent Stem Cells or Fetal Brain Tissue

This study describes an experimental platform to rapidly characterize engineered stem cells and their behaviors before their application in long-term in vivo transplant studies for nervous system rescue and repair.

High Throughput Characterization of Adult Stem Cells Engineered for Delivery of Therapeutic Factors for Neuroprotective Strategies

Generation of induced pluripotent stem cells provides fascinating prospects for the derivation of autologous transplants. However, progression through a pluripotent state and laborious re-differentiation still hinders clinical translation. Here we describe the derivation of adult human fibroblasts and their direct conversion into induced neural progenitor cells and the subsequent differentiation into neural lineages.

Derivation of Adult Human Fibroblasts and their Direct Conversion into Expandable Neural Progenitor Cells

Direct neuronal reprogramming generates neurons that maintain the age of the starting somatic cell. Here, we describe a single vector-based method to generate induced neurons from dermal fibroblasts obtained from adult human donors.

Simple Generation of a High Yield Culture of Induced Neurons from Human Adult Skin Fibroblasts

The protocol presents the reprogramming of peripheral blood mononuclear cells to induce neural stem cells by Sendai virus infection, differentiation of iNSCs into dopaminergic neurons, transplantation of DA precursors into the unilaterally-lesioned Parkinson's disease mouse models, and evaluation of the safety and efficacy of iNSC-derived DA precursors for PD treatment.

Generation of Induced Neural Stem Cells from Peripheral Mononuclear Cells and Differentiation Toward Dopaminergic Neuron Precursors for Transplantation Studies

We present a genetically modified-free (GM-free) method to obtain cells with a neuronal phenotype from reprogrammed peripheral blood cells. Activation of a signaling pathway linked to novel human GPI-linked protein reveals an efficient GM-free method for obtaining human pluripotent stem cells.

GM-Free Generation of Blood-Derived Neuronal Cells

We describe a protocol to reprogram human skin-derived fibroblasts into induced Neuronal Progenitor Cells (iNPCs), and their subsequent differentiation into induced Astrocytes (iAs). This method leads to fast and reproducible generation of iNPCs and iAs in large quantities.

In vitro Modeling for Neurological Diseases using Direct Conversion from Fibroblasts to Neuronal Progenitor Cells and Differentiation into Astrocytes

Transplantation of human pluripotent stem cell-derived GABAergic neurons generated by neuronal programming could be a potential treatment approach for neurodevelopmental disorders. This protocol describes the generation and transplantation of human stem cell-derived GABAergic neuronal precursors into the brains of neonatal mice, allowing long-term investigation of grafted neurons and evaluation of their therapeutic potential.

Transplantation of Human Stem Cell-Derived GABAergic Neurons into the Early Postnatal Mouse Hippocampus to Mitigate Neurodevelopmental Disorders

Learn chemogenetic regulation of reprogrammed stem cell-derived dopaminergic precursors for treating Parkinson's disease in mouse models. This protocol enables precise neuronal control and functional recovery assessment.

Chemogenetic Regulation in Reprogrammed Stem Cell-derived Precursor Cells in Treating Neurodegenerative Diseases

Explore More Videos